Who has been buying Shinshin Pharmaceutical stock?

5 distinct insiders have filed 7 disclosed insider purchases in Shinshin Pharmaceutical (002800), most recently on 2026-06-30. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Shinshin Pharmaceutical have?

Shinshin Pharmaceutical has 7 buy-side and 4 sell-side disclosures on record, covering ₩126M ($87K) in total reported value, spanning 2021-06-08 to 2026-06-30.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Shinshin Pharmaceutical 002800

Company

신신제약Shinshin Pharmaceutical

Insiders

Buys

Total Value

₩126M ($87K)

Avg Return

-18.20%

Last Filing

2026-06-30

Shinshin Pharmaceutical (002800) has 7 disclosed insider purchases and 4 disclosed disposals on record, filed by 5 distinct insiders. Together those filings cover ₩126M ($87K) in reported transaction value. The earliest filing StockDrifts holds for Shinshin Pharmaceutical is dated 2021-06-08; the most recent is 2026-06-30. Across these filings the average return since disclosure is -18.20%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-06-30	BUY	Market Buy	김상경 Kim Sang-kyung	Managing Director	700	-	-	-
2026-06-29	BUY	Market Buy	김상경 Kim Sang-kyung	Managing Director	500	-	-	-
2026-06-24	BUY	Market Buy	김상경 Kim Sang-kyung	Managing Director	500	-	-	-
2026-06-15	BUY	Market Buy	김상경 Kim Sang-kyung	Managing Director	300	-	-	-
2025-10-27	SELL	Market Sell	윤광철 Gwangcheol Yoon	Managing Director	-5.0K	₩5,400	-16.3%	₩27M ($19K)
2025-10-01	SELL	Market Sell	신성학 divinity	moving	-7.6K	₩5,570	-12.8%	₩43M ($30K)
2025-09-29	BUY	기타	신성학 divinity	moving	6.4K	₩5,660	+10.9%	₩36M ($25K)
2025-01-21	SELL	Market Sell	이종민 Jongmin Lee	Managing Director	-7.5K	₩5,430	-15.7%	₩41M ($28K)
2025-01-20	SELL	Market Sell	이종민 Jongmin Lee	Managing Director	-2.5K	₩5,520	-13.8%	₩14M ($10K)
2025-01-10	BUY	기타	윤광철 Gwangcheol Yoon	Managing Director	5.0K	₩5,700	+10.2%	₩29M ($20K)
2025-01-09	BUY	기타	이종민 Jongmin Lee	Managing Director	10.0K	₩5,700	+10.2%	₩57M ($40K)
2024-03-25	SELL	임원퇴임	박노석 Noseok Park	Other non-executive directors	-46.7K	₩6,750	+7.0%	₩315M ($219K)
2023-07-28	BUY	Market Buy	김상경 Kim Sang-kyung	Managing Director	200	-	-	-
2021-06-09	BUY	Market Buy	박노석 Noseok Park	Other non-executive directors	100	₩8,380	-25.1%	₩838K ($582)
2021-06-08	BUY	Market Buy	박노석 Noseok Park	Other non-executive directors	80	₩8,450	-25.7%	₩676K ($469)

Frequently asked questions

Who has been buying Shinshin Pharmaceutical stock?: 5 distinct insiders have filed 7 disclosed insider purchases in Shinshin Pharmaceutical (002800), most recently on 2026-06-30. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Shinshin Pharmaceutical have?: Shinshin Pharmaceutical has 7 buy-side and 4 sell-side disclosures on record, covering ₩126M ($87K) in total reported value, spanning 2021-06-08 to 2026-06-30.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.